4.6 Article

Epigenetic Modification-Associated Molecular Classification of Gastric Cancer

Journal

LABORATORY INVESTIGATION
Volume 103, Issue 9, Pages -

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.labinv.2023.100170

Keywords

epigenetic modification; gastric cancer; immunotherapy efficacy; prognosis

Ask authors/readers for more resources

We developed an epigenetic modification-associated molecular classification for gastric cancer (GC) and identified signature genes. The classification system was highly associated with clinicopathological characteristics and existing classifications of GC. PIP4P2, an independent prognostic factor of the classification system, played a crucial role in predicting prognosis and immunotherapy efficacy.
Epigenetic modification is involved in tumorigenesis and cancer progression. We developed an epigenetic modification-associated molecular classification of gastric cancer (GC) to identify signature genes that accurately predict prognosis and the efficacy of immunotherapy. Least absolute shrinkage and selection operator and multivariate Cox regression analysis were conducted to develop an epigenetic modification-associated molecular classification. We investigated the significance of PIP4P2, an independent prognostic factor of the classification system, in predicting the prognosis and immunotherapy efficacy of patients with GC. The epigenetic modificationassociated molecular classification was highly associated with the clinicopathological characteristics of patients and the existing classification of GC. PIP4P2 was highly expressed in GC tissue and tumor-associated macrophages. High PIP4P2 expression in GC tissue-induced tumor progression by activating PI3K/AKT signal transduction had a negative impact on immunotherapy efficacy. High expression of PIP4P2 in macrophages was correlated with poor prognosis in patients with GC. PIP4P2 is an independent unfavorable prognostic factor of epigenetic modification-associated molecular classification, is involved in tumorigenic progression, and is essential for assessing the prognosis and immunotherapy efficacy of GC.& COPY; 2023 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available